Notably, the levels of plasma p‐tau181 not only highly predict tau pathologies but also specifically reflect amyloid plaque pathology in the discovery cohorts (n = 36, AUC = 0.98), identifying Alzheimer's disease from other neurodegenerative disorders.57 This evidence concerns the gene MAPT and Alzheimer disease.